Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
about
The cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy.Selection and evolution of resistance to antimicrobial drugs.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo.Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention ConcentrationsIn vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.Is there a role for antimicrobial stewardship in cystic fibrosis?Morphology engineering of Streptomyces coelicolor M145 by sub-inhibitory concentrations of antibiotics.
P2860
Q35861377-D43B8098-8377-4A41-92F6-9E004161DD50Q38220609-94F34CAD-5B6A-46A2-95A0-DD9FECBC46B1Q38579967-1446B6FE-70DF-413E-8BDC-0F5F83B21CF1Q39361363-A0F3BA8F-49AF-4ED0-BFA0-EBB7613DC511Q40312701-9EBC292C-2969-41B2-A900-55E5874D1884Q40499211-1CA4A229-B94C-422C-930D-E8D10083AE49Q40697349-847E99FE-9041-4417-B03E-9831D473F66FQ41098639-5E69A6DC-30A7-4A5B-A5E8-B6ED6D6C14E1Q41388208-38E050BC-4FBC-47F2-9DD7-B8AA838B4184Q41648730-C84F2541-2E6B-45F4-A879-E8900A472063Q42202818-C2D83857-9A9F-4FE0-BE36-063056033CA7Q42379003-6D80C70F-9ECB-4C57-BB91-2BCED225C43C
P2860
Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Resistance development of cyst ...... obic and anaerobic conditions.
@ast
Resistance development of cyst ...... obic and anaerobic conditions.
@en
Resistance development of cyst ...... obic and anaerobic conditions.
@nl
type
label
Resistance development of cyst ...... obic and anaerobic conditions.
@ast
Resistance development of cyst ...... obic and anaerobic conditions.
@en
Resistance development of cyst ...... obic and anaerobic conditions.
@nl
prefLabel
Resistance development of cyst ...... obic and anaerobic conditions.
@ast
Resistance development of cyst ...... obic and anaerobic conditions.
@en
Resistance development of cyst ...... obic and anaerobic conditions.
@nl
P2093
P2860
P1433
P1476
Resistance development of cyst ...... obic and anaerobic conditions.
@en
P2093
Gerard McCaughey
Matt McKevitt
Paul Diamond
P2860
P304
P356
10.1371/JOURNAL.PONE.0069763
P407
P577
2013-07-25T00:00:00Z